PITTSBURGH — One of Pittsburgh's newest publicly traded companies is investing in Pittsburgh in a major way, breaking ground Friday on a new $75 million to $100 million pharmaceutical manufacturing facility near Pittsburgh International Airport that will double the biotech firm's employee base.
Krystal Biotech Inc. (Nasdaq: KRYS) is a gene therapy company that creates products to treat rare skin diseases. One of its products, KB103, treats an often-fatal skin blistering condition among children called Dystrophic epidermolysis bullosa. The South Side-based Krystal has an existing smaller production facility, about 7,500 square feet, on the South Side.
Read more in the Pittsburgh Business Times.
TRENDING NOW:
© 2020 Pittsburgh Business Times
/cloudfront-us-east-1.images.arcpublishing.com/cmg/XCUXZC2XYZHCRGNNGKFEX6U3LQ.png)
